Genprex Inc (NASDAQ:GNPX) Receives Consensus Rating of “Hold” from Analysts

Genprex Inc (NASDAQ:GNPX) has earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

Zacks has also assigned Genprex an industry rank of 58 out of 256 based on the ratings given to related companies.

A number of brokerages have weighed in on GNPX. Noble Financial began coverage on shares of Genprex in a report on Monday, April 29th. They issued an “outperform” rating and a $5.00 price target on the stock. Zacks Investment Research raised shares of HAYS PLC/ADR from a “sell” rating to a “hold” rating in a research report on Tuesday, June 18th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Cytori Therapeutics in a research note on Monday, April 1st.

Genprex stock traded up $0.09 during midday trading on Friday, reaching $1.18. 157,900 shares of the stock traded hands, compared to its average volume of 41,149. The business’s fifty day moving average price is $1.30. Genprex has a 12 month low of $0.95 and a 12 month high of $7.88. The company has a market cap of $16.54 million, a PE ratio of -1.31 and a beta of 1.49.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.09. On average, analysts anticipate that Genprex will post -0.87 EPS for the current fiscal year.

About Genprex

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Featured Story: Buyback For Investors Defined

Get a free copy of the Zacks research report on Genprex (GNPX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.